Albumin-Creatinine Ratio: Normal Ranges and Management
Normal and Abnormal Ranges
The normal urine albumin-to-creatinine ratio (UACR) is <30 mg/g creatinine; moderately increased albuminuria (microalbuminuria) is 30–299 mg/g; and severely increased albuminuria (macroalbuminuria) is ≥300 mg/g. 1, 2
These thresholds are consistent across major guidelines:
| Category | UACR (mg/g) | 24-hour collection (mg/24h) | Timed collection (μg/min) |
|---|---|---|---|
| Normal (A1) | <30 | <30 | <20 |
| Moderately increased (A2) | 30–299 | 30–299 | 20–200 |
| Severely increased (A3) | ≥300 | ≥300 | ≥200 |
Screening Recommendations
Type 2 diabetes: Perform annual UACR screening starting at diagnosis. 1, 4
Type 1 diabetes: Perform annual UACR screening beginning 5 years after diagnosis (or at puberty, whichever comes first). 1, 2, 4
All patients with diabetes should also have annual serum creatinine and eGFR measurements, because 20–40% of diabetic CKD patients have reduced eGFR without albuminuria. 1, 2
Preferred Testing Method
Use a spot urine UACR on a random sample—preferably first-morning void—rather than timed or 24-hour collections. 1, 2, 4
- First-morning specimens reduce diurnal variation and avoid orthostatic proteinuria, which is particularly important in adolescents. 1, 4
- Timed or 24-hour collections are more burdensome and add little predictive accuracy. 1, 2
- Never measure albumin concentration alone without creatinine correction, because urine concentration varies widely with hydration and produces unreliable results. 1, 4
- Never rely on standard urine dipstick protein tests, as they only become positive at >300–500 mg/day and miss microalbuminuria entirely. 1, 4, 5
Confirmation of Persistent Albuminuria
A single elevated UACR does not establish persistent albuminuria; at least 2 of 3 specimens collected within a 3–6 month interval must be ≥30 mg/g to confirm persistence. 3, 1, 2, 4
This requirement mitigates false-positives caused by:
- Biological variability (>20% between measurements even in stable individuals). 2, 6
- Transient elevators: vigorous exercise within 24 hours, urinary tract infection, fever or acute illness, congestive heart failure exacerbation, marked hyperglycemia, marked hypertension, pregnancy, or hematuria. 3, 1, 4
Patients should avoid vigorous exercise for 24 hours before each urine collection and be free of acute illness, infection, or uncontrolled blood pressure/glucose at the time of sampling. 1, 4
Management of Moderately Increased Albuminuria (30–299 mg/g)
After Confirming Persistent Elevation (≥2 of 3 positive tests):
Initiate an ACE inhibitor or ARB regardless of the current blood pressure level. 1, 2, 4
- ACE-I/ARB therapy has been shown to delay progression from micro- to macroalbuminuria and reduce cardiovascular mortality. 4, 5, 7
- Monitor serum creatinine and potassium after starting ACE-I/ARB to detect hyperkalemia or acute kidney injury. 4
- Do not start ACE-I/ARB therapy based on a single elevated UACR or when UACR is normal (<30 mg/g) with normal blood pressure, as this provides no benefit and may cause harm. 4
Additional Interventions:
- Target blood pressure <130/80 mmHg regardless of baseline hypertension status. 1, 4, 5
- Optimize glycemic control to reduce the risk of diabetic kidney disease progression. 4
- Continue annual UACR and eGFR monitoring. 1, 4
Management of Severely Increased Albuminuria (≥300 mg/g)
Strongly recommend ACE-I or ARB therapy in all patients with macroalbuminuria. 4
- Consider referral to nephrology when eGFR <60 mL/min/1.73 m² or when atypical features are present. 2, 4
- Increase monitoring frequency to semi-annual or quarterly assessments. 4
When to Suspect Non-Diabetic Kidney Disease and Refer to Nephrology
Refer when any of the following are present:
- Rapidly declining eGFR or rapidly increasing albuminuria. 3, 2, 4
- Active urinary sediment (RBCs, WBCs, or cellular casts). 3, 2, 4
- Gross hematuria. 4
- Type 1 diabetes with kidney disease but no retinopathy (rare presentation). 3, 2, 4
- Nephrotic syndrome (edema, hypoalbuminemia, hyperlipidemia). 1
- Refractory hypertension. 3
- >30% reduction in eGFR within 2–3 months after initiating ACE-I/ARB. 3
- Uncertainty regarding the etiology of kidney disease. 2, 4
Monitoring Frequency After Diagnosis
- Annual UACR and eGFR for all patients with confirmed albuminuria. 1, 4
- Semi-annual or quarterly monitoring when eGFR <60 mL/min/1.73 m² or when albuminuria is progressing. 4
- Patients with already documented CKD should increase UACR monitoring to 1–4 times per year, tailored to CKD stage. 4
Common Pitfalls to Avoid
- Never diagnose persistent albuminuria on a single elevated test; require ≥2 of 3 positive results over 3–6 months. 3, 1, 2, 4
- Never rely on standard urine dipstick protein tests for screening—they miss microalbuminuria. 1, 4, 5
- Never measure albumin concentration without creatinine correction; results are unreliable due to hydration variability. 1, 4
- Do not assume a normal UACR excludes kidney disease; 20–40% of diabetic CKD patients have reduced eGFR without albuminuria. 1, 2, 4
- Do not start ACE-I/ARB therapy before confirming persistent elevation, to avoid unnecessary risks (hyperkalemia, acute kidney injury) without proven benefit. 4
- Up to 40% of patients with a single elevated UACR will have spontaneous remission on repeat testing, underscoring the importance of confirmation. 4